PFE- Pfizer Inc.
Healthcare · Drug Manufacturers - General
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 26 analysts
12-Month Price Target
$28.88
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $27.84
Graham Number
√(22.5 × EPS × Book Value)
$15.99
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$27.33
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
7/10
78% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
5.0%Return on equity - measures how efficiently capital is used
Positive profit margin
6.8%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+2.6%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
74.25×Low financial leverage reduces risk of distress
Current ratio above 1
1.27×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.1B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
6.20%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Nov 3, 2026
42
days
EPS (TTM)
$0.76
P/E (TTM)
36.6
Fwd P/E
9.6
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
6.20%
5Y Avg Annual
$1.5860
Last Payment
$0.4300
Ex-Date
07/24/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest07/24/2026 | 09/01/2026 | $0.4300 | 6.18% |
05/08/2026 | 06/16/2026 | $0.4300 | 6.18% |
01/23/2026 | 03/03/2026 | $0.4300 | 6.18% |
11/07/2025 | 12/16/2025 | $0.4300 | 6.18% |
07/25/2025 | 09/02/2025 | $0.4300 | 6.18% |
05/09/2025 | 06/17/2025 | $0.4300 | 6.18% |
01/24/2025 | 03/04/2025 | $0.4300 | 6.18% |
11/08/2024 | 12/17/2024 | $0.4200 | 6.04% |
Magic Number
Shares needed to self-fund your next purchase
$27.84
Price
$0.4300
Last div. (quarterly)
65
shares
Own 65 PFE shares ($1,809.28) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$1,809.28
New shares / year
+4 shares
Dividend Calculator
6.18% yieldEstimate PFE dividend income at the current rate.
Per year
$617.93
Per month
$51.49
≈ 359.3 shares at $1.72/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
PFE vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
New York, United States
Employees
75,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Pfizer Inc. (PFE) stock trades at $27.84, up 0.34% on the day. With a market capitalization of $158.65 billion, PFE is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 36.6, a forward P/E of 9.6 and earnings per share (EPS) of $0.76. Over the most recent period the company reported 3% year-over-year revenue growth and a net profit margin of 6.8%. Below you'll find PFE's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
PFE - Frequently Asked Questions
Is Pfizer Inc. (PFE) a good stock to buy in 2026?
Pfizer Inc. (PFE) shows risks such as high leverage (debt/equity of 74.3). Whether PFE is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is PFE's stock price today?
Pfizer Inc. (PFE) trades at $27.84, up 0.34% on the session. Prices on this page update throughout the trading day.
Does PFE pay a dividend?
Yes. Pfizer Inc. pays an annual dividend of $1.72 per share, a dividend yield of 6.20%. The most recent ex-dividend date was July 24, 2026. Its payout ratio is about 226% of earnings.
Is PFE overvalued?
With a P/E ratio of 36.6×, PFE is valued above the broad-market average for the healthcare sector. Its PEG ratio is 12.65. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is PFE's market cap?
Pfizer Inc. (PFE) has a market capitalization of $158.65 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.